Petros Pharmaceuticals (PTPI) Separates from Executive Mitchell Arnold

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Petros Pharmaceuticals has separated from Mitchell Arnold, an executive, effective June 18, 2026. In exchange for a general release of claims against the company, Arnold will receive two months of base salary, acceleration of 3,000 unvested shares, and up to two months of COBRA health-insurance premium coverage.

Petros Pharmaceuticals, Inc. (PTPI) has separated from Mitchell Arnold, an executive at the company, according to a separation and severance agreement filed June 18, 2026.

Severance Terms

Arnold's employment ended on June 18, 2026. Under the agreement, the company will pay him:

Two months of base salary, minus taxes and payroll deductions, in equal installments starting with the first payroll date after the agreement becomes final
3,000 previously unvested shares under a restricted stock award agreement dated February 19, 2025, which will now vest immediately on the separation date
A one-time cash payment of $100 to cover estimated taxes on the stock vesting
Up to two months of premium payments for health, dental, and vision coverage under COBRA (a federal law allowing employees to continue employer insurance after leaving), if Arnold elects to participate

Arnold will also receive payment for 12.5 accrued but unused paid time off days, totaling $11,105.77 after taxes and deductions.

Terms of the Agreement

In exchange for these payments, Arnold released all claims against the company, including claims related to discrimination, harassment, retaliation, and other employment-related disputes. He agreed to keep the company's confidential information private, assist in transitioning his work responsibilities, and cooperate with any future government or legal investigations involving the company.

Arnold cannot seek further employment or engagement with the company. He also agreed not to make disparaging public statements about the company or its officers, directors, employees, or business practices.

The agreement was signed June 18, 2026. Arnold had 21 days to consider it and seven days after signing to revoke his acceptance.

Key facts

Petros Pharmaceuticals, Inc. (PTPI) separated from executive Mitchell Arnold effective June 18, 2026

Arnold receives two months of base salary as severance

3,000 previously unvested restricted shares will immediately vest on the separation date

Company will pay up to two months of COBRA health-insurance premiums

Arnold receives $11,105.77 for 12.5 accrued paid time off days (after taxes)

Arnold executed a full release of all claims against the company

Arnold agreed to non-disparagement and confidentiality obligations

Agreement filed as 8-K Item 5.02 (officer departure) on June 18, 2026

Why it matters

Executive departures signal potential organizational changes and can affect investor confidence, particularly in smaller pharmaceutical companies where key personnel often drive strategy and operations. The fact that Petros accelerated vesting of 3,000 shares as part of the separation suggests an orderly transition, but the filing provides no information about Arnold's title, tenure, or the reason for his departure. For investors, the real question is whether this affects the company's drug development pipeline, clinical programs, or commercial operations—details not disclosed in the severance agreement itself.

Frequently asked

Who left Petros Pharmaceuticals and when?

Mitchell Arnold separated from the company effective June 18, 2026. The separation agreement was signed on the same date.

What compensation did Arnold receive?

Arnold received two months of base salary, immediate vesting of 3,000 restricted shares, $100 for estimated taxes on the stock, payment for 12.5 unused paid time off days ($11,105.77 after taxes), and up to two months of health-insurance premium coverage.

What restrictions apply to Arnold after his departure?

Arnold agreed to keep the company's confidential information private forever, assist in transitioning his responsibilities, cooperate with future investigations, not seek re-employment with the company, and not make disparaging public statements about the company or its officers and employees.

Did Arnold release his right to sue the company?

Yes. Arnold executed a broad release of all claims against the company, including employment-related claims. However, he retained the right to report violations to government agencies like the SEC and to file complaints with the EEOC.

What the filing reported

5.02 Departure/Election of Directors or Officers

9.01 Financial Statements & Exhibits